|
健保碼及健保價 |
|
See related Onbrez Breezhaler inhalation powd cap[昂舒 吸入膠囊] information |
|
|
|
製造商 |
Novartis |
|
代理/經銷商 |
Novartis |
|
成份 |
Indacaterol maleate |
|
適應症 |
Maintenance bronchodilator treatment of airflow obstruction in patients with COPD. |
|
用量 |
150 mcg cap once daily inhalation. Max: 300 mcg once daily. |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
注意事項 |
Asthma, CV disorders (CAD, acute MI, cardiac arrhythmias, HTN); convulsive disorders or thyrotoxicosis, patients responsive to β2-adrenergic agonists. Discontinue use when pulse rate & BP increases. For inhalation use only. Monitor plasma glucose more closely in diabetic patients upon initiation of treatment. Pregnancy & lactation. |
|
不良反應 |
Nasopharyngitis, upper resp tract infection, sinusitis, cough, pharyngolaryngeal pain, rhinorrhea, respiratory tract congestion. Headache, ischemic heart disease, muscle spasms, peripheral edema.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Concomitant administration of other sympathomimetic agents (alone or as part of combination therapy). Other long-acting β2-adrenergic agonists. Methylxanthine derivatives, steroids, non-K-sparing diuretics can potentiate possible hypokalemic effect. β-adrenergic blockers (including eye drops)
View more drug interactions with Onbrez Breezhaler[昂舒] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Onbrez Breezhaler 吸入用膠囊 |
|
Onbrez Breezhaler 150 mcg x 30's |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Novartis
|
|
|
|
